AzTrials
AzTrials

Gastrointestinal Disorder, FunctionalNCT04530929

Analysis of the Impact of Used Probiotic Strains and Diet on Body Composition, Cardiopulmonary Efficiency and the Incidence of Gastrointestinal Disorders in Runners

A study testing SANPROBI BARRIER in people with Gastrointestinal Disorder, Functional, run by Medical University of Bialystok at 1 site in Poland.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The aim of the study was to assess the diet and the effect of probiotic therapy on reducing the incidence of gastrointestinal disorders and selected parameters determining the inflammation of the body, body composition, cardiopulmonary efficiency and selected serum biochemical parameters. Read more about this study

Who is it for?
Ages 20 to 60 yearsHealthy volunteers can take part
Conditions the study is for
Gastrointestinal Disorder, Functional
What is being tested?
SANPROBI BARRIER
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
66 participants
Where
1 sitePoland
Study dates
1 Mar 2018to 31 Dec 2018
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 20 to 60 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • women and men aged 20-60,
  • running trainings over 5 km/day

Who cannot join

  • use (other than in research) probiotics
  • pacemaker

Trial locations and contacts

1 site in 1 country.

Poland1 site
  • Medical University of Bialystok

    Bialystok, 15-089

Other trials in Poland

About this study

The aim of the study was to assess the diet and the effect of probiotic therapy on reducing the incidence of gastrointestinal disorders and selected parameters determining the inflammation of the body, body composition, cardiopulmonary efficiency and selected serum biochemical parameters.

70 competitors took part in the study. The research was carried out at the Department of Dietetics and Clinical Nutrition (Medical University of Bialystok), Fitness Club Maniac Gym in Bialystok, as well as at the Hematological Diagnostics Department and the Biochemical Diagnostics Department of the University Teaching Hospital in Bialystok.

Read more

The study was randomized using a double-blind trial. 35 persons selected in the draw were G1 group and the remaining G2 group (n=35). The intervention factor was the SANPROBI BARRIER multi-strain probiotic or placebo. Competitors used probiotic/ placebo for three months at a dose of 2x2 capsules daily (2.5 x 10 9 CFU / g (1 capsule)). The consent of the Bioethics Committee of the Medical University, no. RI-002/81/2017, was obtained for the study.

The study consisted of two stages (W1 and W2), and each stage was associated with three visits by the participants. The first of these (W1) included qualification for the study, completing the questionnaire and 3-day nutrition diaries. At the second visit, body composition analysis and cardiopulmonary efficiency test on a medical treadmill were performed. For morphological tests (blood count with smear, lipid profile, fasting glucose, C-reactive protein and ionogram) at the third visit for each competitor was collected blood from the vein in the amount of 10 ml. The final stage (W2) included similar three visits, where the first visit was made after 3 months of taking product A or B. 66 competitors took part in it.

Read the detailed description

The aim of the study was to assess the diet and the effect of probiotic therapy on reducing the incidence of gastrointestinal disorders and selected parameters determining the inflammation of the body, body composition, cardiopulmonary efficiency and selected serum biochemical parameters.

The approved of the Bioethics Committee of the Medical University, no. RI-002/81/2017, was obtained for the study. 70 people meeting the inclusion criteria were included in the intervention and observational study. The research was carried out at the Department of Dietetics and Clinical Nutrition at the Faculty of Health Sciences of the Medical University of Bialystok, Fitness Club Maniac Gym in Bialystok, as well as at the Hematological Diagnostics Department and the Biochemical Diagnostics Department of the University Clinical Hospital in Bialystok.

The study took place in the spring (March-June 2018) and autumn (September-December 2018), i.e. during of the most intense period in terms of participation in runners' competitions. The study was randomized using a double-blind trial. 35 persons selected in the draw were G1 group and the remaining G2 group (n=35). The tests were completely anonymous, the competitors gave their informed written consent to carry them out.

Interventional study was conducted using a probiotic or placebo. The observation period lasted three months. The intervention factor was the SANPROBI BARRIER multi-strain probiotic (commonly available in pharmacies) or placebo (created on the model of a probiotic capsule, specially for the needs of research, by Sanprobi Sp. z o.o.). Competitors used probiotic/ placebo for three months at a dose of 2x2 capsules daily (2.5 x 10 9 CFU / g (1 capsule)). The probiotic used in the study contained bacterial strains, i.e. Bifidobacterium lactis W52, Lactobacillus brevis W63, Lactobacillus casei W56, Lactococcus lactis W19, Lactococcus lactis W58, Lactobacillus acidophilus W37, Bifidobacterium bifidum W23, Lactobacillus salivarius W24. Players and researchers were not informed about the type of capsule taken (probiotic or placebo). Competitors were asked to use product A or B after blood tests.

Each player had 3 visits during the preliminary stage (W1) and 3 visits of the final stage (W2).

Preliminary stage (W1)

  1. The first visit took place in the Department of Dietetics and Clinical Nutrition at the Medical University of Bialystok. It included qualification for the study based on the criteria for inclusion in the study group, discussion of the purpose of the study and signing the written consent for the study by the participants, as well as information about the protection of their personal data and full anonymity. Each participant received an individual code (e.g. A01, A02, B01, B02 etc.), which was used to identify the subject in further stages. Athletes were asked not to use other probiotic strains than those used in the study. All competitors completed a survey regarding demographic data, information on dietary supplementation used, the incidence of gastrointestinal disorders, and 3-day nutrition diary.
  2. The second visit took place after a week. Each player was invited to the Maniac Gym Fitness Club in Bialystok. Body composition analysis was performed using an InBody 770 analyzer (InBody, Korea). To determine the level of cardiopulmonary efficiency using the Bruce protocol test on a medical treadmill were performed. Then, competitors were issued a referral for laboratory tests. During this meeting, in accordance with the simple draw product A (group G1) was given to every second person, and product B (group G2) for the remaining persons.
  3. For morphological tests (blood count with smear, lipid profile, fasting glucose, C-reactive protein and ionogram) at the third visit for each competitor was collected blood from the vein in the amount of 10 ml.

Final stage (W2) The final stage consisted of three visits (similar to the preliminary stage). The first visit was made after 3 months of taking product A or B by the competitors. 66 people took part in the final stage of the study (G1 = 34 people, G2 = 32 people). One person from group G1 (product A) did not report for the final visit without providing a specific reason. Three people from the G2 control group (product B) did not participate in the final stage of the study (W2) due to injury (2 people) and without providing a specific reason (1 person).

  • The first visit took place at the Department of Dietetics and Clinical Nutrition (Medical University of Bialystok) where competitors were completed the questionnaires to determine the changes in the incidence of gastrointestinal disorders.
  • The second visit was conducted at the Fitness Club Maniac Gym, where the cardiopulmonary fitness test and body composition analysis were carried out.
  • Third visit took place at the Hematological Diagnostics Department of the University Teaching Hospital in Bialystok, where from each participant the blood was collected (from the vein) in an amount of 10 ml for biochemical tests (as during the initial stage at visit 3). 3-day nutrition diary: Each participant described customary meals consumed for the next three days, including two working days and one day off. The food diary includes hours of meals, the weight of products and dishes, and the amount of fluids consumed during the day. The competitors were asked to use the standard, current diet, without any significant changes. The energy value of the daily nutritional plan, the content of the main nutrients, vitamins, minerals, cholesterol and dietary fiber were taken into account in the evaluation of the three-day nutrition diary. Then, the percentage of compliance with the norm for the energy supply of diet and nutrients was assessed by comparing the results to Polish norms for healthy, adult men and women, and based on scientific research on the discipline of long-distance running.

Body composition analysis All competitors underwent body composition analysis using the InBody model 770 analyzer (South Korea). The body composition analyzer, using the electrical bioimpedance principle, uses low current flow using 6 frequencies and subsequent measurement of the resistance of individual tissues to determine body composition. The following parameters were assessed: body weight (kg), body fat content in kilograms and percent, visceral fat content (cm2), skeletal muscle mass (kg), body water content (kg). Before the test, the participants were informed about the need to stay fasting 8-12 hours and a minimum of 24 hours after physical activity. They were asked to avoid drinking liquids 1 h before the test. None of the competitors had an implanted pacemaker, which is an absolute exclusion criterion in the study of body composition analysis by electrical bioimpedance.

Analysis of cardiopulmonary efficiency In order to determine the cardiopulmonary efficiency of competitors, the Fitmate MED device (Cosmed, Italy) was used, which comprehensively determined cardiopulmonary efficiency and a medical treadmill adapted to this type of HpCosmos analysis (Germany). The Fitmate MED device is equipped with a sensor that enables the measurement of inhaled and exhaled air as well as a mask containing disposable mouthpieces and antibacterial filters. To monitor cardiac contractions, a Garmin sporttester model HRM-Tri 010-10997-09 (United States) was used. In cardiopulmonary fitness tests, a walking treadmill test was used according to Bruce's protocol. The exercise test included effort progression to increase walking speed and incline of the treadmill. The study was divided into 5 stages (3 minutes each). In the first of them, the walk took place at a speed of 2.7 km/h and a 10% incline of the treadmill. In the second stage, the treadmill accelerated to 4 km/h, and the incline increased to 12%. The third stage is a speed of 5.5 km / h and a incline 14%. The fourth stage is the speed increase to 6.8 km / h and the treadmill inclination 16%, and the last stage 5 is the speed of 8 km / h and the inclination of the treadmill 18%. Participants were informed that the cardiorespiratory fitness test should take place for a minimum of 2 weeks after intense physical effort (marathon, ultramarathon). During the test, the maximum test procedure was used to obtain more test parameters, and the test condition was considered to be 90% HRmax by the test subject, or the test could not be continued by interrupting it at the test subject's request. None of the competitors tested completed the test alone, they all reached the 90% HR max limit.

Laboratory tests The tests were performed after venous blood collection (from a vein in the arm) in the amount of 10 ml. Twice (during the initial and final stages) the following measurements were taken: complete blood count with smear, fasting glucose, total cholesterol, HDL, LDL and triglycerides, sodium, iron, potassium, magnesium, serum calcium, determination C-reactive protein (CRP) concentrations. In order to determine pro-inflammatory cytokines, blood was collected on a clot, it was subjected to centrifugation, and after clot separation, the obtained serum was stored at -80 degrees Celsius (until the tests were performed). To determine the concentration of interleukin 6 (IL-6) and tumor necrosis factor (TNF-alpha), the ELISA method (enzyme-linked immunosorbent assay) was used, using R\&D System kits (Bio-Techne, United States) according to the manufacturer's instructions.

Being tested
SANPROBI BARRIER, PLACEBO
Keywords
probiotic, gastrointestinal disorder, long-distance running, body composition, cardiopulmonary efficiency
Medical subject headings
Gastrointestinal Diseases

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • SANPROBI BARRIERDietary supplement

    Competitors used probiotic for three months at a dose of 2x2 capsules daily (2.5 x 109 CFU / g (1 capsule)).

  • PLACEBODietary supplement

    Competitors used placebo for three months at a dose of 2x2 capsules daily.

Study groups in NCT04530929
Study groupRoleWhat they receive
Group PROBIOTICActive comparatorThe intervention factor was the SANPROBI BARRIER multi-strain probiotic (commonly available in pharmacies). Competitors used probiotic for three months at a dose of 2x2 capsules daily (2.5 x 109 CFU / g (1 capsule)).
Receives: Dietary Supplement: SANPROBI BARRIER
Group PLACEBOPlacebo comparatorPlacebo created on the model of a probiotic capsule, specially for the needs of research, by Sanprobi Sp. z o.o.. Competitors used placebo for three months at a dose of 2x2 capsules daily.
Receives: Dietary Supplement: PLACEBO

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Influence of probiotic Sanprobi Barrier on the occurrence of gastrointestinal disorders of long-distance runners.

    Subjective assessment (survey) of changes in the incidence and severity of gastrointestinal disorders in group of long-distance runners.

    Another survey at the beginning and end of the study.

    Measured: 12 weeks (assessment at baseline and after 3 months of probiotic / placebo use)

  2. Influence of probiotic Sanprobi Barrier on the body composition of long-distance runners.

    Assessment of runner's body composition changes (body composition analysis used InBody 770 body composition analyzer).

    The following parameters were assessed: body weight (kg), body fat content in kilograms and percent, visceral fat content (cm2), skeletal muscle mass (kg), body water content (kg).

    Measured: 12 weeks (assessment at baseline and after 3 months of probiotic / placebo use)

  3. Influence of probiotic Sanprobi Barrier on the cardiopulmonary efficiency of long-distance runners.

    Assessment of changes in cardiopulmonary efficiency of long-distance runners (testing the player's efficiency on a medical treadmill with the use of a sport tester and an oxygen mask. Bruce Test Protocol).

    Measured: 12 weeks (assessment at baseline and after 3 months of probiotic / placebo use)

  4. Influence of probiotic Sanprobi Barrier on general inflammation of the body.

    Assessment of changes in parameters (C-reactive protein, TNF-alpha, IL-6) from blood.

    Measured: 12 weeks (assessment at baseline and after 3 months of probiotic / placebo use)

  5. Influence of probiotic Sanprobi Barrier on blood biochemical parameters.

    Assessment of changes in parameters (complete blood count with smear, fasting glucose, total cholesterol, HDL, LDL and triglycerides, sodium, iron, potassium, magnesium, serum calcium) from blood.

    Measured: 12 weeks (assessment at baseline and after 3 months of probiotic / placebo use)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted28 Aug 2020
  2. Study start1 Mar 2018
  3. Primary completion31 Dec 2018
  4. Study completion31 Dec 2018

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Model description
70 people meeting the inclusion criteria were included in the intervention and observational study. The study was randomized using a double-blind trial. 35 persons selected in the draw were G1 group and the remaining G2 group (n=35). The tests were completely anonymous, the competitors gave their informed written consent to carry them out. Interventional study was conducted using a probiotic or placebo. The intervention factor was the SANPROBI BARRIER multi-strain probiotic (commonly available in pharmacies) or placebo (created on the model of a probiotic capsule, specially for the needs of research, by Sanprobi Sp. z o.o.). Competitors used probiotic/ placebo for three months at a dose of 2x2 capsules daily (2.5 x 109 CFU / g (1 capsule)).
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
66 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04530929
Sponsor's protocol ID
N/ST/MN/18/003/3316
Status last verified
Aug 2020
First submitted
10 Aug 2020
Last updated
28 Aug 2020
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Videbaek S, Bueno AM, Nielsen RO, Rasmussen S. Incidence of Running-Related Injuries Per 1000 h of running in Different Types of Runners: A Systematic Review and Meta-Analysis. Sports Med. 2015 Jul;45(7):1017-26. doi: 10.1007/s40279-015-0333-8.

    PubMed 25951917
  • Vitale K, Getzin A. Nutrition and Supplement Update for the Endurance Athlete: Review and Recommendations. Nutrients. 2019 Jun 7;11(6):1289. doi: 10.3390/nu11061289.

    PubMed 31181616
  • Cox AJ, Pyne DB, Saunders PU, Fricker PA. Oral administration of the probiotic Lactobacillus fermentum VRI-003 and mucosal immunity in endurance athletes. Br J Sports Med. 2010 Mar;44(4):222-6. doi: 10.1136/bjsm.2007.044628. Epub 2008 Feb 13.

    PubMed 18272539
  • Hill C, Guarner F, Reid G, Gibson GR, Merenstein DJ, Pot B, Morelli L, Canani RB, Flint HJ, Salminen S, Calder PC, Sanders ME. Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol. 2014 Aug;11(8):506-14. doi: 10.1038/nrgastro.2014.66. Epub 2014 Jun 10.

    PubMed 24912386
  • Huang WC, Lee MC, Lee CC, Ng KS, Hsu YJ, Tsai TY, Young SL, Lin JS, Huang CC. Effect of Lactobacillus plantarum TWK10 on Exercise Physiological Adaptation, Performance, and Body Composition in Healthy Humans. Nutrients. 2019 Nov 19;11(11):2836. doi: 10.3390/nu11112836.

    PubMed 31752370
  • Jager R, Mohr AE, Carpenter KC, Kerksick CM, Purpura M, Moussa A, Townsend JR, Lamprecht M, West NP, Black K, Gleeson M, Pyne DB, Wells SD, Arent SM, Smith-Ryan AE, Kreider RB, Campbell BI, Bannock L, Scheiman J, Wissent CJ, Pane M, Kalman DS, Pugh JN, Ter Haar JA, Antonio J. International Society of Sports Nutrition Position Stand: Probiotics. J Int Soc Sports Nutr. 2019 Dec 21;16(1):62. doi: 10.1186/s12970-019-0329-0.

    PubMed 31864419
  • West NP, Pyne DB, Cripps AW, Hopkins WG, Eskesen DC, Jairath A, Christophersen CT, Conlon MA, Fricker PA. Lactobacillus fermentum (PCC(R)) supplementation and gastrointestinal and respiratory-tract illness symptoms: a randomised control trial in athletes. Nutr J. 2011 Apr 11;10:30. doi: 10.1186/1475-2891-10-30.

    PubMed 21477383
  • Leite GSF, Resende Master Student AS, West NP, Lancha AH Jr. Probiotics and sports: A new magic bullet? Nutrition. 2019 Apr;60:152-160. doi: 10.1016/j.nut.2018.09.023. Epub 2018 Oct 22.

    PubMed 30590242
  • Clark A, Mach N. Exercise-induced stress behavior, gut-microbiota-brain axis and diet: a systematic review for athletes. J Int Soc Sports Nutr. 2016 Nov 24;13:43. doi: 10.1186/s12970-016-0155-6. eCollection 2016.

    PubMed 27924137
  • Holland AM, Hyatt HW, Smuder AJ, Sollanek KJ, Morton AB, Roberts MD, Kavazis AN. Influence of endurance exercise training on antioxidant enzymes, tight junction proteins, and inflammatory markers in the rat ileum. BMC Res Notes. 2015 Sep 30;8:514. doi: 10.1186/s13104-015-1500-6.

    PubMed 26423686
  • Pugh JN, Sparks AS, Doran DA, Fleming SC, Langan-Evans C, Kirk B, Fearn R, Morton JP, Close GL. Four weeks of probiotic supplementation reduces GI symptoms during a marathon race. Eur J Appl Physiol. 2019 Jul;119(7):1491-1501. doi: 10.1007/s00421-019-04136-3. Epub 2019 Apr 13.

    PubMed 30982100
  • Besselink MG, van Santvoort HC, Renooij W, de Smet MB, Boermeester MA, Fischer K, Timmerman HM, Ahmed Ali U, Cirkel GA, Bollen TL, van Ramshorst B, Schaapherder AF, Witteman BJ, Ploeg RJ, van Goor H, van Laarhoven CJ, Tan AC, Brink MA, van der Harst E, Wahab PJ, van Eijck CH, Dejong CH, van Erpecum KJ, Akkermans LM, Gooszen HG; Dutch Acute Pancreatitis Study Group. Intestinal barrier dysfunction in a randomized trial of a specific probiotic composition in acute pancreatitis. Ann Surg. 2009 Nov;250(5):712-9. doi: 10.1097/SLA.0b013e3181bce5bd.

    PubMed 19801929
  • Schmitz L, Ferrari N, Schwiertz A, Rusch K, Woestmann U, Mahabir E, Graf C. Impact of endurance exercise and probiotic supplementation on the intestinal microbiota: a cross-over pilot study. Pilot Feasibility Stud. 2019 Jun 8;5:76. doi: 10.1186/s40814-019-0459-9. eCollection 2019.

    PubMed 31198580
  • Clancy RL, Gleeson M, Cox A, Callister R, Dorrington M, D'Este C, Pang G, Pyne D, Fricker P, Henriksson A. Reversal in fatigued athletes of a defect in interferon gamma secretion after administration of Lactobacillus acidophilus. Br J Sports Med. 2006 Apr;40(4):351-4. doi: 10.1136/bjsm.2005.024364.

    PubMed 16556792
  • West NP, Horn PL, Pyne DB, Gebski VJ, Lahtinen SJ, Fricker PA, Cripps AW. Probiotic supplementation for respiratory and gastrointestinal illness symptoms in healthy physically active individuals. Clin Nutr. 2014 Aug;33(4):581-7. doi: 10.1016/j.clnu.2013.10.002. Epub 2013 Oct 10.

    PubMed 24268677

Questions about this trial

What is this clinical trial studying?

A study testing SANPROBI BARRIER in people with Gastrointestinal Disorder, Functional, run by Medical University of Bialystok at 1 site in Poland.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 28 Aug 2020. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Poland. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Influence of probiotic Sanprobi Barrier on the occurrence of gastrointestinal disorders of long-distance runners. (time frame: 12 weeks (assessment at baseline and after 3 months of probiotic / placebo use)). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04530929, which also lists 29 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Aug 2020.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in